NEW YORK (dpa-AFX Broker) - The US investment bank Goldman Sachs has left its rating for Evonik at "Neutral" with a target price of 21.20 euros following preliminary quarterly figures and a forecast increase. All in all, the specialty chemicals company presented a strong set of figures, analyst Georgina Fraser wrote in a study published on Monday. According to discussions she had held with investors in advance, this was also largely expected. The new middle of the forecast range for operating profit for the year means a five percent upside potential for the consensus estimate./ck/la

Publication of the original study: 15.07.2024 / 12:42 / BST

First disclosure of original study: Date not specified in study / Time not specified in study / Time zone not specified in study

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------